Presentation on circulatory immunological biomarkers in cancer patients and novel technologies during
clinical trials
Uxbridge, UK – 15 March 2021 – Immodulon, the immuno-oncology company, announces that its Chief Scientific Officer, Dr. Thomas Kleen, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021. The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, 25 March.
The presentation will discuss several topics including the challenges posed by the identification and validation of various circulatory immunological biomarkers in cancer patients during clinical trials, and the benefits and challenges of using novel technologies and classic immunological biomarkers.
11th World Clinical Biomarkers & Companion Diagnostic Europe Event
The annual Clinical Biomarkers & CDx Europe Summit brings stakeholders together to fast-track precision medicine through clinically validated biomarkers and companion diagnostics partnerships in Europe. The meeting will tackle key conversations spanning biomarker discovery through to drug-Dx market penetration, enabling innovation to power pipeline progression. Featuring the latest tools and techniques validating biomarker utility, overcoming patient selection challenges in rare disease, key clinical case-study learnings shaping diagnostic strategy in addition to the much needed core EU focus on navigating a tricky regulatory and reimbursement landscape to prevent incoming regulations hindering the delivery of critical drugs to patients in need. Find out more at www.worldcdxeurope.com
About Immodulon Therapeutics
Immodulon Therapeutics Ltd. (London, UK) is a privately-owned, clinical-stage, immuno-oncology company primarily focused on the development of safe, effective and novel treatments for cancer. Its lead drug candidate, IMM-101, has shown promise in early clinical trials, demonstrating potential for the platform. It contains heat-killed whole cell Mycobacterium obuense which activates dendritic cells and other cells of the innate immune system predominantly via Toll-like receptor 2. It is Immodulon’s vision that IMM-101 will become a backbone immunotherapy across multiple tumour types. Its unique mechanism of action should not only make this product applicable to a range of cancers but, in combination with immune checkpoint inhibitors and any other standard-of care treatment of the four major pillars of cancer therapy – immunotherapy, chemotherapy, radio/ablation therapy and surgery – it is also expected to increase their efficacy without compromising on the patient’s safety and quality of life. For more information about Immodulon, please visit www.immodulon.com .